Forte Biosciences Inc (FBRX) 13F Filing Data & Analysis (Q2 2026)

FBRX ranks #4915 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

87 institutions disclose a position in FBRX, but none treat it as a major bet — even Squadron Capital Management LLC, its most concentrated holder, allocates just 1.5% of its own portfolio to it.

Israel Englander has added to its FBRX position for two straight quarters, increasing it by $7.2M to reach $13.9M today.

Fred Alger Management, LLC has trimmed its FBRX position for two straight quarters, cutting it by $9.2M while still holding $30.6M.

FBRX reported a net loss of $87.9M over the trailing twelve months.

• Not yet profitable — net loss of $87.9M over the trailing twelve months
• Revenue declined 99.8% year over year
• Net income declined year over year, from -$42.5M to -$87.9M
• Operating cash flow was negative, using $50.9M in cash
• Current ratio of 3.88x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.36x equity — within a conventional range